The FDA has cleared a focused-ultrasound developer to compare the safety and efficacy of acoustic energy for treating prostate cancer against the more conservative approach of active surveillance.

Editor David Bluemke, MD, PhD, says the journal’s rising impact factor is “representative of the fundamental importance of imaging throughout our hospitals and clinics.”

An imaging OEM is teaming with a multi-omics diagnostics company to offer lung-cancer care teams lab data alongside radiologic findings and clinical histories.

One of the largest private health insurers in the U.S. has gone from considering hybrid PET/CT for cardiac indications “experimental/investigational” to displaying willingness to pay for the modality. 

Rumors have been swirling for more than a year, but a Siemens Healthineers C-suite executive has declared the company’s ultrasound business alive, well and amply resourced.

A Danish healthtech company has been cleared for European sales of AI software aimed at helping trauma physicians detect and classify fractures.

“More than most companies, Toyota is led from the bottom up as much as from the top down.”

A cancer-care technology company that was acquired by one of the world’s largest imaging OEMs a year ago has received an Investigational Device Exemption from the FDA.